Transition From Sevoflurane to Total Intravenous Anesthesia in Pediatric Patients (TSTP)
8 giugno 2026 aggiornato da: Manuel Cuevas, Hospital de Clinicas José de San Martín
Observational Analysis of the Transition From Inhalational Anesthesia to Total Intravenous Anesthesia Guided by Bispectral Index and the Eleveld Model in Pediatric Patients
his prospective, observational, exploratory, and multicenter study aims to describe the evolution of propofol effect-site concentration administered via target-controlled infusion (TCI) based on the Eleveld model-with adjustments for opioid co-administration-guided by the bispectral index (BIS) during the transition from inhalational anesthesia with sevoflurane to total intravenous anesthesia (TIVA) in pediatric patients.The study population will include 50 pediatric patients, aged 2 to 12 years, scheduled for elective low- or medium-complexity surgeries.
Induction will be performed with sevoflurane, followed by intravenous access placement and transition to TIVA using propofol and remifentanil via TCI.
As part of the neuromonitoring, the bispectral index, spectral edge frequency (SEF), and median frequency (MF) will be recorded.
Additionally, hemodynamic parameters will be recorded on a minute-by-minute basis.The primary objective is to describe BIS-guided adjustments of propofol during the anesthetic transition.
Secondary objectives include describing interindividual variability in propofol titration, time to reach a BIS of 40-60, burst suppression patterns, SEF, MF, drug consumption, hemodynamic stability, and clinical adverse events.
Statistical analysis will be primarily descriptive, examining correlations between BIS, propofol, and the minimum alveolar concentration (MAC) of sevoflurane.
Panoramica dello studio
Stato
Non ancora reclutamento
Tipo di studio
Osservativo
Iscrizione (Stimato)
50
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Contatto studio
- Nome: Manuel Cuevas, MD
- Numero di telefono: 542494675554
- Email: manuel.cuevas@anestesiologo.org
Backup dei contatti dello studio
- Nome: Stella Verlangieri, MD
- Numero di telefono: 541144905757
- Email: sverlangieri@gmail.com
Luoghi di studio
-
-
C.a.b.a.
-
C.a.b.a., C.a.b.a., Argentina, 1270
- Hospital General de Niños Pedro de Elizalde
-
Contatto:
- Gonzalo Alberto Tejeda, MD
- Numero di telefono: +54 9 2314 47-3867
- Email: gonzalotejedamed@gmail.com
-
Contatto:
- Nicolas Alejandro Rzza, MD
- Numero di telefono: +54 9 11 6010-7126
- Email: nicolas.alejandro.rizza@gmail.com
-
Investigatore principale:
- Gonzalo Alberto Tejeda, MD
-
Sub-investigatore:
- Nicolas Alejandro Rizza, MD
-
C.a.b.a., C.a.b.a., Argentina, 1881
- Hospital de Clinicas Jose de San Martin
-
Contatto:
- Manuel Cuevas, MD
- Numero di telefono: 02494675554
- Email: manuel.cuevas@anestesiologo.org
-
Contatto:
- Stella Verlangieri, MD
- Numero di telefono: 54 9 11 4490-5757
- Email: sverlangieri@gmail.com
-
Sub-investigatore:
- Francisco Bornet, MD
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Bambino
Accetta volontari sani
No
Metodo di campionamento
Campione non probabilistico
Popolazione di studio
Pediatric patients aged 2 to 12 years scheduled for elective low- or intermediate-risk surgery at Hospital de Clínicas José de San Martín and Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina.
Recruitment will aim for balanced representation across three age strata (2 to <4 years, 4 to <8 years, and 8 to 12 years), although age stratification is not an inclusion criterion.
Patients will be enrolled by consecutive non-probability sampling over an estimated 4-month period, with a target sample size of 50 participants.
Descrizione
Inclusion Criteria:
- Age 2 to 12 years
- Scheduled for elective low- or intermediate-risk surgery according to the National Institute for Health and Care Excellence (NICE) surgical risk stratification (e.g., tonsillectomy, adenoidectomy, postioplasty, orchidectomy, orchidopexy, inguinal herniorrhaphy)
- American Society of Anesthesiologists (ASA) Physical Status Classification I or II
Exclusion Criteria:
- Refusal of parents/legal guardians to sign informed consent, or refusal of the child to provide assent when applicable
- Cardiovascular or neurological disease that may interfere with anesthesia or with the pharmacokinetic model
- History of allergy or adverse reaction to inhalational or intravenous anesthetic agents used in the protocol
- Airway malformations or conditions that complicate standard intubation or airway management
- Psychological or neurological conditions requiring sedative or hypnotic premedication prior to the anesthetic procedure
- Treatment with drugs that may alter the pharmacokinetics or pharmacodynamics of the anesthetic agents
- Difficult peripheral venous access
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
|---|
|
Pediatric patients undergoing sevoflurane to TIVA transition
Pediatric patients aged 2-12 years scheduled for elective low or intermediate risk surgery, undergoing standard sevoflurane mask induction followed by transition to total intravenous anesthesia with propofol via target-controlled infusion (Eleveld model) and remifentanil, guided by Bispectral Index monitoring.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Temporal evolution of propofol effect-site concentration under Eleveld-model TCI during anesthetic transition
Lasso di tempo: From start of propofol infusion (T0, when sevoflurane MAC = 1.0 for age), until sevoflurane MAC = 0, or a maximum of 15 minutes, whichever occurs first.
|
Pattern of propofol effect-site concentration (Ce) adjustments (mcg/mL) over time during the transition from sevoflurane inhalation anesthesia to TIVA.
Propofol is administered via target-controlled infusion using the Eleveld pharmacokinetic-pharmacodynamic model with adjustment for opioid co-administration.
Ce values are titrated under BIS-guided monitoring to maintain BIS between 40 and 60, as a function of decreasing sevoflurane minimum alveolar concentration.
|
From start of propofol infusion (T0, when sevoflurane MAC = 1.0 for age), until sevoflurane MAC = 0, or a maximum of 15 minutes, whichever occurs first.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Interindividual variability in propofol titration
Lasso di tempo: Throughout the transition period (up to 15 minutes from start of propofol infusion)
|
Distribution of propofol effect-site concentration values required to maintain target BIS, expressed as mean, SD, median, and IQR across patients.
|
Throughout the transition period (up to 15 minutes from start of propofol infusion)
|
|
Time to reach target BIS range (40-60)
Lasso di tempo: Up to 15 minutes from start of propofol infusion.
|
Time elapsed from start of propofol infusion until BIS first reaches 40-60 (minutes).
|
Up to 15 minutes from start of propofol infusion.
|
|
Time outside target BIS range
Lasso di tempo: Up to 15 minutes from start of propofol infusion
|
Cumulative time with BIS <40 and BIS >60 during transition (minutes).
|
Up to 15 minutes from start of propofol infusion
|
|
Duration of cortical suppression episodes
Lasso di tempo: Up to 15 minutes from start of propofol infusion
|
Total time with EEG suppression detected by BIS monitor (minutes).
|
Up to 15 minutes from start of propofol infusion
|
|
Spectral edge frequency (SEF) and median frequency (MF) over time
Lasso di tempo: Up to 15 minutes from start of propofol infusion
|
Time course of SEF and MF (Hz) recorded minute by minute from processed EEG.
|
Up to 15 minutes from start of propofol infusion
|
|
Incidence of intraoperative hemodynamic adverse events
Lasso di tempo: Up to 15 minutes from start of propofol infusion
|
Frequency of hypotension (≥20% drop in MAP from baseline), hypertension (≥20% rise in MAP from baseline), bradycardia (HR below age-adjusted normal range), and tachycardia (HR above age-adjusted normal range).
|
Up to 15 minutes from start of propofol infusion
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Collaboratori
Investigatori
- Investigatore principale: Manuel Cuevas, MD, Hospital de Clinicas Jose de San Martin
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Pubblicazioni generali
- Purdon PL, Sampson A, Pavone KJ, Brown EN. Clinical Electroencephalography for Anesthesiologists: Part I: Background and Basic Signatures. Anesthesiology. 2015 Oct;123(4):937-60. doi: 10.1097/ALN.0000000000000841.
- Lee JM, Akeju O, Terzakis K, Pavone KJ, Deng H, Houle TT, Firth PG, Shank ES, Brown EN, Purdon PL. A Prospective Study of Age-dependent Changes in Propofol-induced Electroencephalogram Oscillations in Children. Anesthesiology. 2017 Aug;127(2):293-306. doi: 10.1097/ALN.0000000000001717.
- Degoute CS, Macabeo C, Dubreuil C, Duclaux R, Banssillon V. EEG bispectral index and hypnotic component of anaesthesia induced by sevoflurane: comparison between children and adults. Br J Anaesth. 2001 Feb;86(2):209-12. doi: 10.1093/bja/86.2.209.
- McFarlan CS, Anderson BJ, Short TG. The use of propofol infusions in paediatric anaesthesia: a practical guide. Paediatr Anaesth. 1999;9(3):209-16.
- Kreuer S, Wilhelm W. The Narcotrend monitor. Best Pract Res Clin Anaesthesiol. 2006 Mar;20(1):111-9. doi: 10.1016/j.bpa.2005.08.010.
- Eleveld DJ, Colin P, Absalom AR, Struys MMRF. Pharmacokinetic-pharmacodynamic model for propofol for broad application in anaesthesia and sedation. Br J Anaesth. 2018 May;120(5):942-959. doi: 10.1016/j.bja.2018.01.018. Epub 2018 Mar 12.
- Nimmo AF, Absalom AR, Bagshaw O, Biswas A, Cook TM, Costello A, Grimes S, Mulvey D, Shinde S, Whitehouse T, Wiles MD. Guidelines for the safe practice of total intravenous anaesthesia (TIVA): Joint Guidelines from the Association of Anaesthetists and the Society for Intravenous Anaesthesia. Anaesthesia. 2019 Feb;74(2):211-224. doi: 10.1111/anae.14428. Epub 2018 Oct 31.
- Vellinga R, Hannivoort LN, Introna M, Touw DJ, Absalom AR, Eleveld DJ, Struys MMRF. Prospective clinical validation of the Eleveld propofol pharmacokinetic-pharmacodynamic model in general anaesthesia. Br J Anaesth. 2021 Feb;126(2):386-394. doi: 10.1016/j.bja.2020.10.027. Epub 2020 Dec 13.
- Eleveld DJ, Proost JH, Vereecke H, Absalom AR, Olofsen E, Vuyk J, Struys MMRF. An Allometric Model of Remifentanil Pharmacokinetics and Pharmacodynamics. Anesthesiology. 2017 Jun;126(6):1005-1018. doi: 10.1097/ALN.0000000000001634.
- Dennhardt N, Boethig D, Beck C, Heiderich S, Boehne M, Leffler A, Schultz B, Sumpelmann R. Optimization of initial propofol bolus dose for EEG Narcotrend Index-guided transition from sevoflurane induction to intravenous anesthesia in children. Paediatr Anaesth. 2017 Apr;27(4):425-432. doi: 10.1111/pan.13118. Epub 2017 Feb 18.
- Davidson AJ, Sale SM, Wong C, McKeever S, Sheppard S, Chan Z, Williams C. The electroencephalograph during anesthesia and emergence in infants and children. Paediatr Anaesth. 2008 Jan;18(1):60-70. doi: 10.1111/j.1460-9592.2007.02359.x.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Stimato)
26 maggio 2026
Completamento primario (Stimato)
31 ottobre 2026
Completamento dello studio (Stimato)
28 marzo 2027
Date di iscrizione allo studio
Primo inviato
6 maggio 2026
Primo inviato che soddisfa i criteri di controllo qualità
8 giugno 2026
Primo Inserito (Effettivo)
12 giugno 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
12 giugno 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
8 giugno 2026
Ultimo verificato
1 giugno 2026
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- PED-TIVA-TRANS
- TSTP01 (Altro identificatore: Hospital de Clínicas José de San Martín)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
INDECISO
Descrizione del piano IPD
A formal individual participant data (IPD) sharing plan has not yet been established.
The current informed consent and assent forms approved by the Ethics Committees do not specifically authorize sharing of individual-level data with third parties; only aggregated, anonymized results are planned for dissemination through scientific publications and conference presentations.
A decision regarding IPD sharing may be reconsidered after study completion, subject to ethics committee approval, additional consent provisions if required, and a formal data sharing agreement.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .